Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapyThis potentially enables treatment for patients...
- Data from the Global, Multiple Ascending Dose Phase 1/2 DELIVER Clinical Trial Anticipated in the Second Half of 2023...
– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by...
POMPANO BEACH, FLORIDA., March 23, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies (“BioStem” or the “Company”) (OTCQB: BSEM), a leading provider...
- Completed enrollment of CT1812 Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease - Received FDA clearance for Phase 2...
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed...
– Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in...
Patent provides intellectual property protection until December 2040PH-HFpEF affects more than 1,600,000 North Americans, with estimates indicating a prevalence of more...
Partnership with Ferrum Health offers unprecedented data security and an integrated AI platform to streamline health systems’ adoption of AI...
Patent developed in collaboration with Syngene International Ltd.MINNEAPOLIS, March 22, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a...
SILVER SPRING, Md. and IRVINE, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company...
2022 CLINICAL AND REGULATORY HIGHLIGHTS Awarded $2 million grant from U.S. Food and Drug Administration (FDA) for the Phase 2...
BOTHELL, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and co-CEO,...
VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate...
Major progress in development of vilobelimab Phase III study in PG announced following detailed feedback and recommendations from the U.S....
-- Agreement extends existing partnership ---- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area...
CHICAGO and TORONTO, March 21, 2023 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF),...
Proceeds from the financing commitment will be used to enhance the launch and commercialization of Scilex’s three FDA-approved non-opioid pain...
DEERFIELD, Ill., March 21, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on...